Frequent questions

• How is Kleresca^® Rosacea Treatment different from other available treatments for this skin condition?

  The Kleresca^® technology offers non-destructive, non-systemic, and painless treatments that use fluorescent light (FLE) energy to stimulate the skin’s natural balance, reducing pimples, redness, and flushing^2-13. The treatment is based on the interaction between a specially designed gel and the Kleresca^® Light. Chromophores in the gel convert the blue light from the Kleresca^® Light into fluorescent light energy that penetrates the skin and activates its healing responses¹³.

• What are biophotonics?

  In this context, biophotonic refers to the interaction between the light and your skin^9,10. Kleresca^®’s biophotonic treatment represents a completely new way of treating rosacea.

• What is the meaning of photobiomodulation?

  Photobiomodulation is a mechanism where light stimulates the cells in the body leading to different beneficial clinical effects and stimulation of its own repair mechanisms^9,10. It has already been used for the treatment of Acne and for Skin Rejuvenation with very positive results^3-6.

• How is the fluorescence created?

  The chromophores in the gel convert the blue light from the lamp into fluorescent light energy that covers the spectra from green over yellow and orange to red at once^2,3,12. The fluorescence generated (dynamic, ultrafast pulsing light) penetrates the different layers of the skin, triggering documented healing responses and activating its healing mechanisms^2,3,12.

• What are the benefits of Kleresca^® Rosacea Treatment?

  Kleresca^® Rosacea Treatment is an effective, non-destructive, and painless treatment that targets unpleasant stinging and burning sensations^9-13.  

  - Treats redness, flushing, and pimples
  - Reduces burning and stinging sensations
  - Fast results
  - Suitable all year-round, including summer

• Why is microvascularisation a benefit?^2,13

  The treatment promotes the development of blood vessels in the treated skin. Contrary to what you might think, this actually reduces erythema and blushing. New blood vessels can disperse the blood accumulated and at the same time nourish the cells with oxygen and nutrients, helping them in their activities.

• What is the recommended protocol¹?

  The recommended protocol depends on the rosacea type and the severity of its symptoms. We recommend that you assess the severity and type of rosacea, as well as quality of the patients’ skin before deciding on the best protocol for them. The total number of treatments generally varies between 4 to 6, once or twice per week, depending on the rosacea type and its severity.

• Which patients are suited for Kleresca^® Rosacea Treatment?

  Scientific publications have shown the effectiveness and safety on the treatment in erythematotelangiectatic and papulopustular rosacea, as well as showing improvements in phymatous rosacea. This includes an overall improvement of the skin quality and rosacea signs and symptoms in all the treated patients^1-3. 

• Can it be used in combination with other techniques?

  Kleresca^® Rosacea Treatment can be combined with other rosacea treatments, but this is always subject to the judgement of the treating clinician or practitioner^1,13.

• What is the difference between Kleresca^® FLE treatments and PDT?

  PDT (Photodynamic Therapy) is a form of phototherapy that involves light and a topical drug that gets activated with the light. The drug will get absorbed by the patient’s skin and then be activated with the light to induce a destruction of skin cells for the treatment of some skin conditions. FLE, on the other hand, is non-destructive, non-systemic and painless alternative to drugs. The gel is not being absorbed, it is only used to convert the blue light of the Kleresca^® Light into Fluorescent Light Energy (FLE). Only the light will penetrate the skin and activate its own repair mechanisms.

• Which products are currently available on the Kleresca^® Technology platform?

  Currently, four products are available on the Kleresca^® Technology platform: Kleresca^® Rosacea Treatment, Kleresca^® Acne Treatment, Kleresca^® Skin Rejuvenation and Kleresca^® Pre-Post Treatment. Each indication features a specifically formulated gel. This is then utilized with specific pre-programmed settings in the Kleresca^® Light. 

• Is the light harmful?

  The Kleresca^® Rosacea Treatment uses a multi-LED lamp (Light Emitting Diode) as its energy source. Harmful UV light is not emitted by the system. With different publications showing high safety and efficacy, Kleresca^® Rosacea Treatment is a well-tolerated treatment with no serious side effects reported.

• Can any LED lamp be used?

  The patented Kleresca^® Light, with pre-programmed wavelength settings specific to each indication, has been developed and tested to efficiently cause the chromophores to photoconvert blue light, thereby creating fluorescent light energy (FLE)¹³.

• Does the gel penetrate the skin?

  The gel stays on the surface of the skin and its purpose is to convert the light emitted by the lamp into fluorescent light energy (FLE). FLE then provides beneficial effects by way of modulation of the biological processes in the multiple layers of the skin. 

• Can Kleresca^® be used during summer^2-13?

  Yes. Kleresca^® Treatments do not induce photosensitivity and patients do not need to avoid sun exposure during or after the treatments. However, people should protect themselves against the harmful UV light of the sun with sunscreen. Kleresca^® FLE treatments are generally gentle and comfortable. Being non-invasive, there is no destruction or removal of the skin’s natural barriers. The gel used during the treatment is not absorbed by the skin, so no substance in it can induce a photosensitive reaction.

• What type of training is provided to professional clinic staff?

  The system is easy to use and complementary training is also offered as part of a certification program for clinic staff. Kleresca^® Academy offers complementary information about the technology and the skin as well. The purpose of the Kleresca^® Academy is to broaden your clinic’s staff knowledge as well as to share this knowledge among professionals. 

• Is Kleresca^® Rosacea Treatment safe^2-13?

  Kleresca^® Rosacea Treatment is described as a pleasant and comfortable experience with a high degree of safety and efficacy. The technology has been on the market since 2014 with no serious adverse events reported. Side effects – seen in some patients – are all non-permanent and may include redness and hyperpigmentation (bronzing of an area of the skin). Side effects impact patients differently depending on their skin type.  These possible side effects should be discussed with your patient before starting the treatment in order to manage expectations.

References

1. Kleresca^® Rosacea Treatment Instruction for Use
2. Edge, D. Et al. Fluorescent Light Energy: the future for treating inflammatory skin conditions? J Clin Aesthet Dermatol. 2019;12(5):E61-;E68
3. Jalili, A. 2018. Chromophore gel-assisted phototherapy. A novel and promising photobiomodulation therapy for facial inflammatory skin diseases and skin aging. J Ästhet Chir. 2018. Early online 20 February 
4. Nikolis, A.  et al. An extension of a multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. Int. J. Dermatol. 2017; Accetped
5. Antoniou, C.et al . A multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. 2016; Int J Dermatol, 2016, 55; 1321 -; 1328
6. Mahendran, A. et al. Treatment of erlotinib‐induced acneiform eruption with chromophore gel‐assisted phototherapy. Photodermatol Photoimmuno Photomed, 2018, 1-3
7. Nikolis, A., et al . A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation. Clinical, Cosmetic and Investigational Dermatology, 2016; 9, 115-;25. 
8. Scarcella et al. 2018,. Treatment of solar lentigines using a combination of PICO-Laser and Biophotonic treatment. Clin Case Rep. 2018;00:1-;3.
9. Braun, S.A.& Gerber, P. A photoconverter-gel assited blue light therapy for the treatment of rosacea. Int J Dermatol. 2017 Dec;56(12):1489-1490
10. Sannino, M. et al. A novel platform for treating rosacea subtypes 1, 2 and 3 using fluorescent light. Clin Case Rep. 2018;00:1-;6.
11. Liu, R.C. et al. Treatment of granulomatous rosacea with chromophore gel-assisted phototherapy. Photodermatol Photoimmunol Photomed. 2019;1-;2.
12. Wade et al. 2019 Kleresca^® Biophotonic therapy decreases facial eythema, improves the signs and symptoms of rosácea and increases patient satisfaction: A post-market study (In Press)
13. Nielsen, Schoedt & Bak-Christensen. Clinical Evaluation -; Kleresca^® Biophotonic Treatments. 2017. Kleresca^® Data on File
14. Wilkin, J., et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004 Jun;50(6):907-12.
15. Wilkin, J., et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584-7.
16. Zeichner, A., et al. Quality of Life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018; 11(2):47 -; 52
17. Say, E.M., et al. Treatment Outcomes of Long-Pulsed Nd: YAG Laser for Two Different Subtypes of Rosacea. J Clin Aesthet Dermatol. 2015 Sep;8(9):16-20.
18. J. Spoendlin, J. J. Voegel, S. S. Jick, C. R. Meier. (2012, September). A study on the epidemiology of rosacea in the U.K. British Journal of Dermatology, 167(3), 598-605.
19. Gether. L et al. Incidence and Prevalence of Rosacea: a systematic review and meta-analysis. Br. J. Dermatol 2018 [Epub ahead of print]
20. Stanisław Jarmuda, Niamh O’Reilly, Ryszard Z˙aba, Oliwia Jakubowicz, Andrzej Szkaradkiewicz and Kevin Kavanagh. (2012). Potential role of Demodex mites and bacteria in the induction of rosacea. Journal of Medical Microbiology, 61, 1504-;1510.
21. Thomas Jansen and Gerd Plewig. (1997). Rosacea: classification and treatment. Journal of the Royal Society of Medicine, 144-150.
22. National Rosacea Society. Widespread Facial Disorder May Be Linked to Genetics. www.rosacea.org/press/archive/20080602.php. Retrieved May 2018.